礼来发言人:无论给药方式如何 均不应大规模复配或销售GLP-1仿制品

美股速递
Feb 08

礼来公司明确表态,针对GLP-1类药物的仿制行为提出严正警告。公司发言人强调,任何机构或个人都不应大规模复配或销售此类仿制产品,且这一原则适用于所有给药途径。此番声明直指当前市场上可能存在的违规操作,凸显了企业对药品合规性和患者安全的高度重视。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10